Ayman K Hamouda1, Asti Jackson2, Deniz Bagdas2,3, M Imad Damaj2. 1. Department of Pharmaceutical Sciences, College of Pharmacy, Texas A&M Health Sciences Center MS, Kingsville, TX. 2. Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA. 3. Experimental Animals Breeding and Research Center, Faculty of Medicine, Uludag University, Bursa, Turkey.
Abstract
Introduction: Nicotine withdrawal symptoms are important factors in determining the relapse rate to tobacco smoking and drugs that diminish these symptoms would potentially have a higher success rate as smoking cessation aids. Unlike US Food and Drug administration approved smoke cessation aids (nicotine and varenicline) which act as nicotinic acetylcholine receptors (nAChRs) agonists, desformylflustrabromine (dFBr) acts as a nAChR positive allosteric modulator with higher selectivity to the α4β2 nAChR. In animal studies, dFBr was well tolerated and reduced intravenous nicotine self-administration. In this study, we use behavioral test in mouse model of spontaneous nicotine withdrawal to assess the effect of dFBr on nicotine withdrawal symptoms. Methods: Spontaneous nicotine withdrawal in nicotine-dependent ICR male mice was established 18-24 h after termination (minipump removal) of 14 days infusion of nicotine. After that (day 15), spontaneous signs of nicotine withdrawal were examined in the following order: anxiety-like behaviors, somatic signs, and then hyperalgesia using previously published behavioral protocols. Fifteen minutes before withdrawal signs testing, mice received a subcutaneous acute injection of vehicle or dFBr at the doses of 0.02, 0.1, and 1 mg/kg to determine the effect of dFBr on nicotine withdrawal symptoms. Results: dFBr produced dose-dependent reversal of nicotine withdrawal signs in mouse model of spontaneous nicotine withdrawal. Implications: Positive allosteric modulators of nAChR such as dFBr reduce nicotine withdrawal symptoms supporting the potential clinical use of this novel class of nAChR-based therapeutics as smoking cessation aid.
Introduction: Nicotine withdrawal symptoms are important factors in determining the relapse rate to tobacco smoking and drugs that diminish these symptoms would potentially have a higher success rate as smoking cessation aids. Unlike US Food and Drug administration approved smoke cessation aids (nicotine and varenicline) which act as nicotinic acetylcholine receptors (nAChRs) agonists, desformylflustrabromine (dFBr) acts as a nAChR positive allosteric modulator with higher selectivity to the α4β2 nAChR. In animal studies, dFBr was well tolerated and reduced intravenous nicotine self-administration. In this study, we use behavioral test in mouse model of spontaneous nicotine withdrawal to assess the effect of dFBr on nicotine withdrawal symptoms. Methods: Spontaneous nicotine withdrawal in nicotine-dependent ICR male mice was established 18-24 h after termination (minipump removal) of 14 days infusion of nicotine. After that (day 15), spontaneous signs of nicotine withdrawal were examined in the following order: anxiety-like behaviors, somatic signs, and then hyperalgesia using previously published behavioral protocols. Fifteen minutes before withdrawal signs testing, mice received a subcutaneous acute injection of vehicle or dFBr at the doses of 0.02, 0.1, and 1 mg/kg to determine the effect of dFBr on nicotine withdrawal symptoms. Results:dFBr produced dose-dependent reversal of nicotine withdrawal signs in mouse model of spontaneous nicotine withdrawal. Implications: Positive allosteric modulators of nAChR such as dFBr reduce nicotine withdrawal symptoms supporting the potential clinical use of this novel class of nAChR-based therapeutics as smoking cessation aid.
Authors: David Gonzales; Stephen I Rennard; Mitchell Nides; Cheryl Oncken; Salomon Azoulay; Clare B Billing; Eric J Watsky; Jason Gong; Kathryn E Williams; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: Jin-Sung Kim; Anshul Padnya; Maegan Weltzin; Brian W Edmonds; Marvin K Schulte; Richard A Glennon Journal: Bioorg Med Chem Lett Date: 2007-06-14 Impact factor: 2.823
Authors: Song Xue; Marsida Kallupi; Bin Zhou; Lauren C Smith; Pedro O Miranda; Olivier George; Kim D Janda Journal: Chem Commun (Camb) Date: 2018-02-13 Impact factor: 6.222
Authors: Ayman K Hamouda; Malia R Bautista; Lois S Akinola; Yasmin Alkhlaif; Asti Jackson; Moriah Carper; Wisam B Toma; Sumanta Garai; Yen-Chu Chen; Ganesh A Thakur; Christie D Fowler; M Imad Damaj Journal: Neuropharmacology Date: 2021-04-18 Impact factor: 5.273
Authors: Lauren C Smith; Lani Tieu; Raymond T Suhandynata; Brent Boomhower; Melissa Hoffman; Yadira Sepulveda; Lieselot L G Carrette; Jeremiah D Momper; Robert L Fitzgerald; Kate Hanham; Joseph Dowling; Marsida Kallupi; Olivier George Journal: Psychopharmacology (Berl) Date: 2021-04-28 Impact factor: 4.415
Authors: Farah Deba; Kara Ramos; Matthew Vannoy; Kemburli Munoz; Lois S Akinola; M Imad Damaj; Ayman K Hamouda Journal: Molecules Date: 2020-06-25 Impact factor: 4.411